Robert Mittman is a Rheumatology/Immunology physician. OpenAlex indexes 13 publications with 415 citations (h-index 5).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
61 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202547 payments
- GlaxoSmithKline, LLC.Program year202546 payments
- GENZYME CORPORATIONProgram year202533 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
37%Anti-IgE32.3%Omalizumab99%Xolair1%Part D + Part B<11 patientsLeukotriene Receptor Antagonist2.2%Montelukast Sodium100%Part D≥38 patients+ 4 more classes in this area
Anti-infectives
25.3%Glycopeptide Antibacterial22.1%Vancomycin hcl100%Part B, office-administered≥43 patientsPenicillins with extended spectrum1.5%Amoxicillin-Clavulanate Potass100%Part D≥48 patients+ 3 more classes in this area
Sensory organs
22.3%Aminoglycoside Antibacterial22.1%Tobramycin sulfate100%Part B, office-administered≥43 patientsFluoroquinolone Antibacterial0.2%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE
Clinical Cancer Research
2017 - Unprecedented Opportunity: Using Federal Stimulus Funds to Advance Health IT in California2009
- What California Stands to Gain: the Impact of the Stimulus Package on Healthcare2009
- Impact of Federal Stimulus Efforts on the Privacy and Security of Health Information in California2009
- Using Clinical Information Technology in Chronic Disease Care: Expert Workshop Summary2004
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
David Felson, MD
Boston University
Marc Hochberg, MD
University of Maryland School of Medicine
Philip Mease, MD
Michelle Petri, MD
Johns Hopkins University School of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”